Clinical Trials

INTEGRIS Cancer Institute - Proton Campus
Clinical Research List - February 2017

If you have a potential patient, please call Kellie Larsen Dyer, BA, CCRP CCRC at 405-773-6613

BREAST

NCI CIRB NRG BR003:  “A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with our without Carboplatin for Node-Positive or High Risk Node-Negative Triple-Negative Invasive Breast Cancer.”
NCI-CIRB S1207:  “Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. “  Consider after neo and adjuvant chemo + Oncotype Score >25

NASOPHARYNX

SIGNATURE NOVARTIS CPDR001X2201 “A Phase II, open-level, randomized, controlled study of PDR001 in patients with moderately differentiated/undifferentiated, locally advanced, recurrent or metastatic NPCwho progressed on standard treatment.  For second and third line treatment options.

LUNG

SIGNATURE NOVARTIS CINC280A2201 “A Phase II, Multicenter, four cohort study of oral cMET inhibitor capmatinib (INCB280) in adult patients with EGFR wild-type, advanced non-small cell cancer (NSCLC) who have received one or two prior lines of systemic therapy for advanced/metastatic disease.” For second and third line treatment options.

MELANOMA

NCI-CIRB S1320:  ”A Randomized Phase II Trial of Intermittent versus Continuous Dosing of Dabrafenib (NSC-763760) and  Trametinib  (NSC-763093) in BRAF V600E/K Mutant Melanoma

RENAL

NCI-CIRB E2810: “Randomized, Double Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy.

REGISTRIES

(CARIS) TCREG-001-00-1209 “A Registry of Caris Life Sciences ® Molecular Intelligence ™ Services for Evaluation of Correlation with Clinical Outcomes for Cancer.”  Requires ICIO  Med Onc’s to utilize CARIS tests on tumor blocks prior to being identified as eligible.

INTEGRIS Cancer Institute - INTEGRIS Southwest Medical Center Campus
Clinical Research List - February 2017

If you have a potential patient, please call Kellie Larsen Dyer, BA, CCRP CCRC at 405-773-6613

BREAST

NCI CIRB NRG BR003:  “A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with our without Carboplatin for Node-Positive or High Risk Node-Negative Triple-Negative Invasive Breast Cancer.”
NCI-CIRB S1207:  “Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. “  Consider after neoadjuvant & adjuvant chemo with Recurrent Oncotype Score >25.

LUNG

SIGNATURE NOVARTIS CINC280A2201 “A Phase II, Multicenter, four cohort study of oral cMET inhibitor capmatinib (INCB280) in adult patients with EGFR wild-type, advanced non-small cell cancer (NSCLC) who have received one or two prior lines of systemic therapy for advanced/metastatic disease.” For second and third line treatment options

MELANOMA

NCI-CIRB S1320:  ”A Randomized Phase II Trial of Intermittent versus Continuous Dosing of Dabrafenib (NSC-763760) and  Trametinib  (NSC-763093) in BRAF V600E/K Mutant Melanoma
NCI-CIRB EA6134: "A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma"

MYELOMA

NCI-CIRB E1A11:  “Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE  in Patients with  Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)

NASOPHARYNX

SIGNATURE NOVARTIS CPDR001X2201 “A Phase II, open-level, randomized, controlled study of PDR001 in patients with moderately differentiated/undifferentiated, locally advanced, recurrent or metastatic NPCwho progressed on standard treatment.  For second and third line treatment options.  



© 2017 INTEGRIS Health Pencil
Oklahoma's largest hospital network
3300 N.W. Expressway
Oklahoma City, OK 73112 Phone: (405) 951-2277
Back to Top